This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Le Deley, M.-C. Articles by Hill, C. Search for Related Content PubMed PubMed Citation Articles by Le Deley, M.-C. Articles by Hill, C.

Risk of Secondary Leukemia After a Solid Tumor in Childhood According to the Dose of Epipodophyllotoxins and Anthracyclines: A Case-Control Study by the Société Française d’Oncologie Pédiatrique

Marie-Cécile Le Deley, Thierry Leblanc, Akthar Shamsaldin, Marie-Anne Raquin, Brigitte Lacour, Danièle Sommelet, Agnès Chompret, Jean-Michel Cayuela, Chantal Bayle, Alain Bernheim, Florent de Vathaire, Gilles Vassal, Catherine Hill

From the Biostatistics and Epidemiology Unit, the Radiophysics Unit, the Department of Pediatric Oncology, the Department of Medicine, the Hematology Unit, and the Cytogenetics Laboratory, Institut Gustave-Roussy, Villejuif; the Pediatric Hematology Unit and the Hematology Laboratory, Hôpital Saint-Louis, Paris; INSERM Unit 521, Villejuif; and the Registre Lorrain des Cancers de l’Enfant, Nancy, France.

Address reprint requests to Marie-Cécile Le Deley, MD, Service de Biostatistique et d’Epidémiologie, Institut Gustave Roussy, rue Camille Desmoulins, 94805 Villejuif Cedex, France; email: le_deley{at}igr.fr.

Purpose: To estimate the risk of secondary leukemia as a function of the dose of epipodophyllotoxins and anthracyclines.

Methods: We conducted a case-control study of the risk of secondary leukemia or myelodysplasia after a solid tumor in childhood within the Société Française d’Oncologie Pédiatrique, including 61 patients with leukemia matched with 196 controls. The characteristics of the first cancer, the patient’s family history of cancer, and the treatment (type, cumulative dose of chemotherapy, schedule of etoposide administration, and radiation dose delivered to active bone marrow) were compared in the two groups.

Results: Only two factors were found to increase the risk of leukemia in multivariate analysis, namely, the type of the first tumor, with an excess risk in patients with Hodgkin’s disease (relative risk 6.4; 95% confidence interval [CI], 1.6 to 24) or osteosarcoma (relative risk 5; 95% CI, 1.3 to 19), and exposure to epipodophyllotoxins and anthracyclines. The risk of leukemia increased regularly with the cumulative dose of etoposide. In summary, patients who received between 1.2 and 6 g/m² of epipodophyllotoxins or more than 170 mg/m² of anthracyclines had a seven-fold higher risk (95% CI, 2.6 to 19) compared with patients who received lower doses or none of these drugs. The risk of leukemia in patients who received more than 6 g/m² of epipodophyllotoxins was multiplied by 197 (95% CI, 19 to 2,058). The risk of leukemia was not increased by exposure to alkylating agents or radiotherapy.

Conclusion: Both epipodophyllotoxins and anthracyclines increase the risk of secondary leukemia. The current challenge is to minimize the mutagenic effects of these drugs by diminishing cumulative doses without losing the therapeutic benefits.

Supported by La Ligue Nationale Contre le Cancer and l’Association pour la Recherche sur le Cancer, France.

This article has been cited by other articles:

				B. W. Robinson, N.-K. V. Cheung, C. P. Kolaris, S. C. Jhanwar, J. K. Choi, N. Osheroff, and C. A. Felix Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome Blood, April 1, 2008; 111(7): 3802 - 3812. [Abstract] [Full Text] [PDF]

				S. M. Shankar, N. Marina, M. M. Hudson, D. C. Hodgson, M. J. Adams, W. Landier, S. Bhatia, K. Meeske, M. H. Chen, K. E. Kinahan, et al. Monitoring for Cardiovascular Disease in Survivors of Childhood Cancer: Report From the Cardiovascular Disease Task Force of the Children's Oncology Group Pediatrics, February 1, 2008; 121(2): e387 - e396. [Abstract] [Full Text] [PDF]

				K. Hellmann Dexrazoxane-Associated Risk for Secondary Malignancies in Pediatric Hodgkin's Disease: A Claim Without Evidence J. Clin. Oncol., October 10, 2007; 25(29): 4689 - 4690. [Full Text] [PDF]

				D. F. Bajorin The Graying of Testis Cancer Patients: What Have We Learned? J. Clin. Oncol., October 1, 2007; 25(28): 4341 - 4343. [Full Text] [PDF]

				G. Leone, L. Pagano, D. Ben-Yehuda, and M. T. Voso Therapy-related leukemia and myelodysplasia: susceptibility and incidence Haematologica, October 1, 2007; 92(10): 1389 - 1398. [Abstract] [Full Text] [PDF]

				S. Guerin, M. Hawkins, A. Shamsaldin, C. Guibout, I. Diallo, O. Oberlin, L. Brugieres, and F. de Vathaire Treatment-Adjusted Predisposition to Second Malignant Neoplasms After a Solid Cancer in Childhood: A Case-Control Study J. Clin. Oncol., July 1, 2007; 25(19): 2833 - 2839. [Abstract] [Full Text] [PDF]

				K. K. Matthay, G. Yanik, J. Messina, A. Quach, J. Huberty, S.-C. Cheng, J. Veatch, R. Goldsby, P. Brophy, L. S. Kersun, et al. Phase II Study on the Effect of Disease Sites, Age, and Prior Therapy on Response to Iodine-131-Metaiodobenzylguanidine Therapy in Refractory Neuroblastoma J. Clin. Oncol., March 20, 2007; 25(9): 1054 - 1060. [Abstract] [Full Text] [PDF]

				J. D. Dickerman The Late Effects of Childhood Cancer Therapy Pediatrics, March 1, 2007; 119(3): 554 - 568. [Abstract] [Full Text] [PDF]

				M.-C. Le Deley, F. Suzan, B. Cutuli, S. Delaloge, A. Shamsaldin, C. Linassier, S. Clisant, F. de Vathaire, P. Fenaux, and C. Hill Anthracyclines, Mitoxantrone, Radiotherapy, and Granulocyte Colony-Stimulating Factor: Risk Factors for Leukemia and Myelodysplastic Syndrome After Breast Cancer J. Clin. Oncol., January 20, 2007; 25(3): 292 - 300. [Abstract] [Full Text] [PDF]

				M. Alebouyeh, F. Moussavi, H. Haddad-Deylami, and P. Vossough Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: single institutional results Ann. Onc., December 1, 2005; 16(12): 1936 - 1940. [Abstract] [Full Text] [PDF]

				W. Houck, R. Abonour, G. Vance, and L. H. Einhorn Secondary Leukemias in Refractory Germ Cell Tumor Patients Undergoing Autologous Stem-Cell Transplantation Using High-Dose Etoposide J. Clin. Oncol., June 1, 2004; 22(11): 2155 - 2158. [Abstract] [Full Text] [PDF]

				Y. Y. Tyurina, F. B. Serinkan, V. A. Tyurin, V. Kini, J. C. Yalowich, A. J. Schroit, B. Fadeel, and V. E. Kagan Lipid Antioxidant, Etoposide, Inhibits Phosphatidylserine Externalization and Macrophage Clearance of Apoptotic Cells by Preventing Phosphatidylserine Oxidation J. Biol. Chem., February 13, 2004; 279(7): 6056 - 6064. [Abstract] [Full Text] [PDF]